🔗 Share this article

As the United States proceeds with historic changes to its immunization recommendations, a particular individual appears unexpectedly: Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who first made her name by expressing skepticism about COVID-19 vaccines in the pandemic and has concentrated on potential fatalities following COVID-19 immunization in her recent time at the FDA.

Proposed Shifts to Childhood Immunization Schedule

Public health authorities were set to reveal radical changes to the childhood vaccination calendar in December, synchronizing the US with the Danish immunization schedule, according to reports – a substantial departure that would put the US out of alignment with many the world with insufficient data for public health gain. The announcement has been delayed until the next year.

In place of the top vaccines chief, Dr. Høeg is set to present at the meeting. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to run the center this year.

A Shift at the Regulatory Body

The acting appointment could signify a strengthened alliance between the pharmaceutical and biologics divisions as Høeg and Prasad consolidate power at the FDA – and it signals a greater focus upon rolling back previously authorized immunizations at the FDA.

Høeg has often pushed for halting some pediatric immunization guidelines in the US so as to align more similar to Denmark, a country with universal health coverage and a citizenry about the size of Wisconsin’s.

So far statements, she has continued to focus on vaccination policy – usually the domain of Dr. Prasad, director of the FDA’s CBER – rather than pharmaceutical oversight.

Concerns Over Expertise

Dr. Høeg has little discernible background in medication creation, approval processes or administrative roles, which has been customary for former heads of the biologics center. She has worked at the FDA as a top consultant to the FDA chief and CBER since earlier this year.

“She appears not to have any of the qualifications” for leading the drug-regulation department, stated Jonathan Howard. “She has not conducted a clinical trial. She is not versed in leading a large organization. She is not an expert in industry regulation.”

Past commissioners of the center would “understand regulatory frameworks and the underlying principles of pharmaceutical innovation”, said Janet Woodcock. “Frankly, she has not acquired the kind of background that prior appointees who ran CBER have had.”

The drug center has an enormous workload at the FDA, Woodcock pointed out.

“Everybody just focuses on the innovative therapies, but the generic drug division clears a multitude of generic medications. There’s a biosimilars program, OTC medication office and so forth, and all of those must be looked after,” Dr. Woodcock said. “The area you don’t keep your eye on, that is the part that I always told people is going to cause problems.”

Additionally, a substantial administrative aspect to the job, which supervises over 5,000 staff members. “It’s a huge leadership role, if you do it right,” the former official added.

Agency Reaction and Contentious Programs

When asked about concerns about Høeg’s credentials and whether this assignment signifies greater collaboration among regulatory chiefs on immunizations, a spokesperson responded that the “inquiries are based on incorrect premises”.

“Her experience is consistent with the duties of her role,” the official stated, noting the months Dr. Høeg spent advising the FDA commissioner on “drug safety and oversight research, including computational safety modeling and shot safety tracking”.

As acting director, Høeg assumes responsibility for the agency head's recently launched expedited review system, a controversial expedited drug-approval program that allegedly concerned her predecessors. “By what process are these therapies being picked for this voucher program? Who is making the decisions?” Dr. Howard questioned. “There is a lot of confidentiality going on at the FDA right now.”

Broadly speaking, he said, “the FDA appears to be shifting towards less stringent rules of pharmaceuticals, except for shots.”

Documented Track Record on Immunizations

With immunizations, Høeg has a more documented, if problematic, track record, some experts said. She authored a analysis using unverified public submissions to determine the incidence of heart inflammation following COVID-19 vaccination. She consulted for the Florida top health official Joseph Ladapo, who allegedly have modified findings to suggest Covid vaccinations are more dangerous than they are.

Among her “wish list” for the new federal leadership included altering rules for novel immunizations and halting “unnecessary” vaccines, she said following the vote on a online show. At the FDA, Høeg has reportedly proposed excluding young men from receiving COVID-19 vaccines.

“She is an complete dogmatist who begins with her beliefs and works backwards to accommodate the science in a very misleading, fraudulent fashion,” Howard stated.

Taking Control and a “Revenge Tour”

Høeg joined other skeptics, {like|